Category

Company News

LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors

LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the initial Closing of a $10 million of the $20 million Bridge Financing. The company is also pleased to announce the election of James (Jim) Mazzo to its Board of Directors.
Read More →

Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19.
Read More →